Table 4

Glycemic control during the randomized crossover trial and antenatal closed-loop feasibility phase in participants with booking HbA1c levels ≤7.5% or >7.5% (58 mmol/mol)

Booking HbA1c ≤7.5% (n = 7)Booking HbA1c >7.5% (n = 9)
SAPCLDifference (CL − SAP)28–32 weeks’ gestation32–36 weeks’ gestation>36 weeks’ gestationSAPCLDifference (CL − SAP)28–32 weeks’ gestation32–36 weeks’ gestation>36 weeks’ gestation
Time in target (63–140 mg/dL) (%)69.1*72.1*372.074.077.7*57.0*57.3*0.364.669.068.8*
Time <63 mg/dL (%)1.00−1.01.62.74.1*00.20.23.02.61.5*
Mean glucose (mg/dL)122.4*120.6*−1.8122.4117.0115.2*136.8*142.2*5.4127.8124.2126.0*
  • CL, closed-loop.

  • †The booking HbA1c is the measurement taken at the first antenatal clinic visit after confirmed pregnancy.

  • *Indicates significant difference between participants with HbA1c ≤7.5% and booking HbA1c >7.5% (P < 0.05).